

## OSE Immunotherapeutics Reports on its 2024 General Shareholders' Meeting and the Evolution of the Board of Directors Ready to Drive the Strategic Company's Growth

Nantes, France – June 19, 2024, 6:15pm CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that all the resolutions submitted to a vote at the Combined General Shareholders' Meeting were approved as proposed by OSE Immunotherapeutics' Board of Directors.

Shareholders also approved appointment of four new independent Directors: **Marc Dechamps, Martine George, Markus Goebel** and **Cécile Nguyen-Cluzel** who together bring a wealth of experience from leadership roles in the biopharmaceutical and health financial industry reinforcing the key strategic skills of the Board. The newly installed Board has appointed **Didier Hoch** as its Chairman. He succeeds Dominique Costantini who did not run for a new mandate at this Shareholders' meeting.

**Didier Hoch, of OSE Immunotherapeutics' Chairman of the Board**, comments: *"I am very honoured by the confidence the Board of Directors has placed in me by appointing me as OSE Chairman of the Board. I would like to thank Dominique Costantini for her support and active collaboration throughout the past years. I am very pleased to welcome new international board members, highly experienced pharmaceutical and financial experts who bring strong track record in scientific and medical innovation, business strategy and international scope. Alongside the OSE Management team and Nicolas Poirier, the CEO, they will contribute to further Company's development and growth strategy."*

**Dominique Costantini** adds: *"I am very proud since the founding of OSE to have contributed to its evolution and its current positioning on attractive therapeutic innovations, through the exceptional work carried out by the entire OSE team. I am very pleased with the appointment of Didier Hoch as OSE Chairman and by the support of such a highly qualified Board. Didier's deep knowledge and understanding of the Company and his rich international experience in the pharmaceutical industry fit perfectly with the OSE growth strategy. I am fully confident in the management team, which will be strengthened as part of a succession plan, we have implemented to ensure the continuity of my operational functions."*

The results of each resolution voted on can be found on the Company's website in the "Investor – General Shareholders' Meeting" section: <https://ose-immuno.com/en/general-shareholders-meetings/>

In total, the shareholders who participated in person, by proxy to the chairwoman, by proxy to a third party or by postal vote owned 8,054,991 shares representing 12,131,115 votes, i.e. 37% of the share capital and 44.4% of the voting rights.

The shareholders approved the annual and consolidated financial statements as of December 31, 2023.

The Board of Directors of OSE Immunotherapeutics now includes the 10 following members:

- Didier Hoch, Chairman
- Maryvonne Hiance, Vice-Chairwoman
- Anne-Laure Autret-Cornet, Director representing the employee shareholders and Chief Financial Officer
- Marc Dechamps, independent Director
- Brigitte Dréno, independent Director
- Martine George, independent Director
- Markus Goebel, independent Director
- Eric Leire, independent Director
- Cécile Nguyen-Cluzel, independent Director
- Nicolas Poirier, Director and Chief Executive Officer

#### ABOUT OSE IMMUNOTHERAPEUTICS

OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I). The Company's current well-balanced first-in-class clinical pipeline includes:

- **Tedopi<sup>®</sup>** (immunotherapy activating tumor specific T-cells, off-the-shelf, neoepitope-based): this cancer vaccine is the Company's most advanced product; positive results from the Phase 3 trial (Atalante 1) in Non-Small Cell Lung Cancer patients in secondary resistance after checkpoint inhibitor failure. Other Phase 2 trials, sponsored by clinical oncology groups, of Tedopi<sup>®</sup> in combination are ongoing in solid tumors.
- **OSE-279** (anti-PD1): first positive results in the ongoing Phase 1/2 in solid tumors.
- **OSE-127 - *Iusvertikimab*** (humanized monoclonal antibody antagonist of IL-7 receptor); ongoing Phase 2 in Ulcerative Colitis (sponsor OSE Immunotherapeutics); ongoing preclinical research in leukemia (OSE Immunotherapeutics).
- **FR-104/VEL-101** (anti-CD28 monoclonal antibody): developed in partnership with Veloxis Pharmaceuticals, Inc. in transplantation; ongoing Phase 1/2 in renal transplant (sponsor Nantes University Hospital); successful Phase 1 in the US (sponsor Veloxis Pharmaceuticals, Inc.).
- **Anti-SIRP $\alpha$  monoclonal antibody** developed in partnership with Boehringer Ingelheim in advanced solid tumors and cardiovascular-renal-metabolic diseases (CRM); positive Phase 1 dose escalation results in monotherapy and in combination; Phase 2 in CRM diseases planned to be initiated end of 2024.
- **ABBV-230** (ChemR23 agonist mAb) developed in partnership with AbbVie in chronic inflammation.

OSE Immunotherapeutics expects to generate further significant value from its three proprietary drug discovery platforms, which are central to its ambitious goal to deliver next-generation first-in-class immunotherapies:

- **Pro-resolutive mAb platform** focused on targeting and advancing inflammation resolution and optimizing the therapeutic potential of targeting Neutrophils and Macrophages in I&I. **ABBV-230** (licensed to AbbVie) is the first candidate generated by the platform, additional discovery programs ongoing on new pro-resolutive GPCRs.
- **Myeloid Checkpoint platform** focused on optimizing the therapeutic potential of myeloid cells in IO by targeting immune regulatory receptors expressed by Macrophages and Dendritic cells. **BI 765063** and **BI 770371** (licensed to Boehringer Ingelheim) are the most advanced candidates generated by the platform. Ongoing additional discovery programs, in particular with positive preclinical results obtained in monotherapy with new anti-**CLEC-1** mAbs.

- **BiCKI<sup>®</sup> Platform** is a bifunctional fusion protein platform built on the key backbone component of anti-PD1 combined with a new immunotherapy target to increase anti-tumor efficacy. A first program has been acquired by Boehringer Ingelheim.

Additional information about OSE Immunotherapeutics assets is available on the Company's website: [www.ose-immuno.com](http://www.ose-immuno.com). Click and follow us on X and LinkedIn.

## Contacts

Sylvie Détry  
[sylvie.detry@ose-immuno.com](mailto:sylvie.detry@ose-immuno.com)

Nicolas Poirier  
Chief Executive Officer  
[nicolas.poirier@ose-immuno.com](mailto:nicolas.poirier@ose-immuno.com)

**French Media: FP2COM**  
Florence Portejoie  
[fportejoie@fp2com.fr](mailto:fportejoie@fp2com.fr)  
+33 6 07 768 283

**U.S. Media Contact**  
RooneyPartners LLC  
Kate Barrette  
[kbarrette@rooneypartners.com](mailto:kbarrette@rooneypartners.com)  
+1 212 223 0561

## Forward-looking statements

This press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics' management in light of its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate.

These forward-looking statements include statements typically using conditional and containing verbs such as "expect", "anticipate", "believe", "target", "plan", or "estimate", their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics' shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on April 30, 2024, including the annual financial report for the fiscal year 2023, available on the OSE Immunotherapeutics' website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements.